Catalyst Biosciences Competitors

Amgen (NASDAQ:AMGN) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for Amgen and Catalyst Biosciences, as provided by MarketBeat.com.

Amgen presently has a consensus price target of $256.1905, indicating a potential upside of 3.74%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 4.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Amgen and Catalyst Biosciences' top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Catalyst Biosciences' net margins, return on equity and return on assets.

Summary

Amgen beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 76.8% of Gilead Sciences shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Catalyst Biosciences and Gilead Sciences' net margins, return on equity and return on assets.

Volatility & Risk

Catalyst Biosciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Catalyst Biosciences and Gilead Sciences, as provided by MarketBeat.com.

Catalyst Biosciences presently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Gilead Sciences has a consensus target price of $101.9524, indicating a potential upside of 47.67%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Catalyst Biosciences is more favorable than Gilead Sciences.

Valuation & Earnings

This table compares Catalyst Biosciences and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 82.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Catalyst Biosciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Catalyst Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Catalyst Biosciences and Regeneron Pharmaceuticals, as provided by MarketBeat.

Catalyst Biosciences currently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Regeneron Pharmaceuticals has a consensus target price of $659.0588, indicating a potential upside of 12.65%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Catalyst Biosciences and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Catalyst Biosciences on 11 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 89.9% of Vertex Pharmaceuticals shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Catalyst Biosciences and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Catalyst Biosciences and Vertex Pharmaceuticals, as provided by MarketBeat.

Catalyst Biosciences currently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Vertex Pharmaceuticals has a consensus target price of $264.4444, indicating a potential upside of 31.98%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Catalyst Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Catalyst Biosciences and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Catalyst Biosciences on 10 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Biogen and Catalyst Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Biogen and Catalyst Biosciences' revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Institutional & Insider Ownership

83.3% of Biogen shares are held by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 4.0% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Biogen and Catalyst Biosciences, as reported by MarketBeat.com.

Biogen currently has a consensus price target of $385.3252, indicating a potential upside of 18.74%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Biogen.

Summary

Biogen beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Catalyst Biosciences' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Catalyst Biosciences, as reported by MarketBeat.

Alexion Pharmaceuticals currently has a consensus price target of $158.4444, indicating a potential downside of 13.18%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Catalyst Biosciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

82.9% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Catalyst Biosciences on 10 of the 14 factors compared between the two stocks.